WOCKPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListHere’s the intraday trading analysis for WOCKPHARMA based on the provided parameters
IntraDay Trade Rating: 4.0
| Stock Code | WOCKPHARMA | Market Cap | 28,725 Cr. | Current Price | 1,772 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 98.4 | Book Value | 190 ₹ | Dividend Yield | 0.00 % | ROCE | 9.74 % |
| ROE | 9.99 % | Face Value | 5.00 ₹ | DMA 50 | 1,481 ₹ | DMA 200 | 1,406 ₹ |
| Chg in FII Hold | 0.09 % | Chg in DII Hold | 0.41 % | PAT Qtr | 132 Cr. | PAT Prev Qtr | 38.0 Cr. |
| RSI | 72.3 | MACD | 72.5 | Volume | 21,26,715 | Avg Vol 1Wk | 16,02,155 |
| Low price | 1,087 ₹ | High price | 1,870 ₹ | PEG Ratio | 2.04 | Debt to equity | 0.64 |
| 52w Index | 87.4 % | Qtr Profit Var | 230 % | EPS | 19.5 ₹ | Industry PE | 31.6 |
📈 Optimal Buy Price: 1,760 – 1,780 ₹ (near current support)
🎯 Profit Exit Levels: 1,820 ₹ (short-term resistance), 1,850 ₹ (extended resistance)
🛑 Stop-Loss: 1,740 ₹ (below immediate support)
🔄 Intraday Exit Guidance: If already holding, consider exiting near 1,820–1,850 ₹ if RSI crosses 75 or MACD momentum slows. Current RSI (72.3) is overbought, while MACD (72.5) shows strong bullish momentum. Volume is above average, supporting intraday trades, but caution is advised due to stretched valuations.
Positive
- Quarterly PAT surged from 38 Cr. to 132 Cr. (+230%).
- Price trading well above DMA 50 (1,481 ₹) and DMA 200 (1,406 ₹), confirming bullish trend.
- EPS of 19.5 ₹ supports valuation strength.
- Institutional inflows (FII +0.09%, DII +0.41%) show confidence.
- Strong trading volume (21.2 lakh vs avg 16 lakh) indicates active intraday participation.
Limitation
- Very high P/E (98.4) vs industry average (31.6), indicating overvaluation.
- Debt-to-equity ratio of 0.64 adds leverage risk.
- ROCE (9.74%) and ROE (9.99%) are modest compared to peers.
- RSI (72.3) close to overbought zone, raising risk of profit booking.
- PEG ratio of 2.04 highlights expensive growth valuation.
Company Negative News
- No major external negative news, but high valuation and leverage remain concerns.
Company Positive News
- Strong quarterly PAT growth and increase in institutional holdings highlight investor confidence.
Industry
- Industry P/E at 31.6 shows sector trading at much lower multiples compared to WOCKPHARMA.
- Pharma sector outlook remains steady, but WOCKPHARMA trades at a premium valuation.
Conclusion
⚖️ WOCKPHARMA is a strong but risky intraday candidate. Technicals show strong bullishness with price above key moving averages and positive momentum, but fundamentals are stretched with high valuations, leverage, and modest efficiency ratios. Suitable for aggressive intraday trades with tight stop-losses and quick profit booking near resistance levels.
Would you like me to extend this into a short-term breakout study or a leverage risk analysis to refine the intraday outlook?